Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. PureTech Health plc
  6. News
  7. Summary
    PRTC   GB00BY2Z0H74

PURETECH HEALTH PLC

(PRTC)
  Report
Delayed London Stock Exchange  -  11:35:17 2023-01-27 am EST
252.50 GBX   -2.88%
01/10Transcript : PureTech Health plc Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-10-2023 02:15 PM
CI
01/06PureTech Health Says ADHD Treatment Study Achieves Primary Efficacy Outcome
MT
01/06PureTech says ADHD treatment shows improved attentional functioning
AN
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

PureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol Leveraging PureTech’s Glyph™ Platform

11/30/2022 | 07:00am EST

PureTech Health plc announced the nomination of a new therapeutic candidate, LYT-310, which is an oral cannabidiol (CBD) prodrug and the second therapeutic candidate developed from PureTech's Glyph™ platform to be advanced toward the clinic. Clinical studies of LYT-310 are expected to begin in Fourth Quarter of 2023. In multiple preclinical models, including large animal and non-human primate, LYT-310 has demonstrated a three to fourfold increase in oral exposure vs.

unmodified CBD in a fasted state. This has the potential to translate into improved safety and reduced side effects. Lymphatic transport has also been confirmed in preclinical models, with up to 30% of LYT-310 entering the lymphatics, compared to 5% for unmodified CBD – which further supports the novel Glyph mechanism of enhancing bioavailability.

The first candidate from the Glyph technology platform, LYT-300 (oral allopregnanolone), is currently being evaluated in a multi-part Phase 1 trial designed to demonstrate oral bioavailability, evaluate safety and tolerability across a range of doses, and to inform dose selection moving forward. The first objective was achieved earlier this year, and LYT-300 demonstrated oral bioavailability of allopregnanolone approximately ninefold greater than that of orally administered allopregnanolone, based on previously published data. The Phase 1 clinical trial is expected to be completed by the end of 2022, and – based on the data – a Phase 1b/2a clinical trial is planned to initiate in 2023.


ę S&P Capital IQ 2022
All news about PURETECH HEALTH PLC
01/10Transcript : PureTech Health plc Presents at 41st Annual J.P. Morgan Healthca..
CI
01/06PureTech Health Says ADHD Treatment Study Achieves Primary Efficacy Outcome
MT
01/06PureTech says ADHD treatment shows improved attentional functioning
AN
2022TRADING UPDATES: Fiinu teams with TransUnion; GRC wins pact
AN
2022PureTech Provides End of Year Report on Key Progress
BU
2022PureTech Health plc Announces Executive Changes
CI
2022PureTech's LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerabil..
BU
2022PureTech Health plc Announces Topline Results from the Completed, Multi-Part Phase 1 Tr..
CI
2022PureTech to Present at 41st Annual J.P. Morgan Healthcare Conference
BU
2022PureTech Founded Entity Sonde Health Raises $19.25 Million Series B for Voice-Based Hea..
AQ
More news
Analyst Recommendations on PURETECH HEALTH PLC
More recommendations
Financials (USD)
Sales 2022 11,3 M - -
Net income 2022 -88,6 M - -
Net cash 2022 398 M - -
P/E ratio 2022 -8,04x
Yield 2022 -
Capitalization 896 M 898 M -
EV / Sales 2022 44,0x
EV / Sales 2023 50,6x
Nbr of Employees 95
Free-Float 84,4%
Chart PURETECH HEALTH PLC
Duration : Period :
PureTech Health plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PURETECH HEALTH PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 3,21 $
Average target price 7,31 $
Spread / Average Target 128%
EPS Revisions
Managers and Directors
Daphne Zohar Chief Executive Officer & Executive Director
Bharatt M. Chowrira President, COO, CFO, Secretary & Director
Christopher A. Viehbacher Chairman
Joseph B. Bolen Chief Scientific Officer
Julie Krop Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PURETECH HEALTH PLC-2.44%896
MODERNA, INC.7.49%74 239
LONZA GROUP AG17.19%42 748
IQVIA HOLDINGS INC.11.53%42 445
ALNYLAM PHARMACEUTICALS, INC.-3.63%28 492
SEAGEN INC.8.70%25 936